Forest Builds On Saunders’ Strategy With $2.9B Aptalis Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma makes its first acquisition of the New Year, tucking in gastrointestinal and cystic fibrosis franchises, which bolster its current therapeutic area offerings.